文献速递脊柱关节炎

整合影像学与生物标志物评估以更好地定义银屑病关节炎并预测生物制剂治疗反应

Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本综述探讨银屑病关节炎(PsA)中预测生物制剂治疗反应的因素,指出约40%患者对一线抗TNF-α治疗无反应,附附着点炎在发病、诊断和预后中的作用及其与纤维肌痛、慢性疼痛和机械性附着点病的鉴别困难。整合影像学、临床评估与生物标志物分析可能有助于实现PsA的分层医学和更好的治疗决策。

要点

  • 约40%的PsA患者对一线抗TNF-α治疗无反应,缺乏指导生物制剂选择和切换的数据。
  • 附着点炎参与PsA的发病、诊断和预后,主要表现为压痛,难以与纤维肌痛、慢性疼痛和机械性附着点病区分。
  • 过多脂肪组织使临床检测关节肿胀更困难,许多PsA患者BMI很高。

核心结论

  • 整合影像学与临床评估及生物标志物分析可能有助于实现PsA的分层医学并改善治疗决策。
  • 这可能包括确定哪些患者需要持续生物制剂治疗、应选择哪类生物制剂,以及哪些患者 alternatively 需要非炎症性疾病的管理。

研究设计与样本

  • 本综述 examined 当前对治疗反应预测因素的理解。
  • 综述讨论了影像学技术进展用于更好地研究银屑病疾病和定义疾病活动度,包括滑膜炎和附着点炎。

主要发现

  • 约40%的PsA患者对一线抗TNF-α治疗无反应。
  • 附着点炎似乎是所有各种PsA临床表现中的共同主线。
  • 附着点炎主要表现为压痛,难以与纤维肌痛、慢性疼痛和机械性附着点病区分,这可能与理解现有治疗 apparent 40%失败相关。
  • 过多脂肪组织使临床检测关节肿胀更困难,因为许多PsA患者BMI很高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment options for PsA have substantially expanded over the last decade. Approximately 40% of patients will not respond to first-line anti-TNF-α therapies. There is limited data to help clinicians select the most appropriate biologic therapy for PsA patients, including guidance for decisions on biologic therapy switching. In this review we will examine the current understanding of predictors of response to treatment. Imaging technology has evolved to allow us to better study psoriatic disease and define disease activity, including synovitis and enthesitis. Enthesitis is implicated in the pathogenesis, diagnosis and prognosis of PsA. It appears to be a common thread among all of the various PsA clinical presentations. Enthesitis mainly manifests as tenderness, which is difficult to distinguish from FM, chronic pain and mechanically associated enthesopathy, and it might be relevant for understanding the apparent 40% failure of existing therapy. Excess adipose tissue makes if more difficult to detect joint swelling clinically, as many PsA patients have very high BMIs. Integrating imaging and clinical assessment with biomarker analysis could help to deliver stratified medicine in PsA and allow better treatment decision making. This could include which patients require ongoing biologic therapy, which class of biologic therapy that should be, and who alternatively requires management of non-inflammatory disease.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Elliott A, McGonagle D, Rooney M, et al. Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy. Rheumatology (Oxford). 2021. PMID: 34951926. doi:10.1093/rheumatology/keab504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。